Matricellular proteins and inflammatory cells: A task force to promote or defeat cancer?

Cytokine and Growth Factor Reviews

Volumn 21, Issue 1, 2010, Pages 67-76

  Llera, Andrea Sabina ^a   Girotti, Maria Romina ^a   Benedetti, Lorena Gabriela ^a   Podhajcer, Osvaldo Luis ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Cancer; Inflammation; Matricellular proteins; SPARC

Indexed keywords

ANTIINFLAMMATORY AGENT; B7 ANTIGEN; BCG VACCINE; BETA1 INTEGRIN; COMPLEMENTARY RNA; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS LIGAND; GALECTIN; GELATINASE A; GELATINASE B; HELICOBACTER PYLORI VACCINE; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEONECTIN; OSTEOPONTIN; SCLEROPROTEIN; SHORT HAIRPIN RNA; T LYMPHOCYTE RECEPTOR; TENASCIN; THROMBOSPONDIN 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER IMMUNIZATION; CANCER INHIBITION; CARCINOGENESIS; COLON CANCER; CYTOKINE RELEASE; DRUG EFFICACY; ESOPHAGUS CANCER; HELICOBACTER INFECTION; HUMAN; INFLAMMATION; INFLAMMATORY CELL; INNATE IMMUNITY; LUNG CANCER; LUNG EMPHYSEMA; MELANOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; STOMACH CANCER; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR PROMOTION; WOUND HEALING;

ANIMALS; CHEMOKINES; CYTOKINES; EXTRACELLULAR MATRIX PROTEINS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MODELS, IMMUNOLOGICAL; NEOPLASMS; OSTEONECTIN; WOUND HEALING;

EID: 77549087662     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2009.11.010     Document Type: Article

References (137)

1. Tlsty T.D., and Coussens L.M. Tumor stroma and regulation of cancer development. Annu Rev Pathol 1 (2006) 119-150
2. Drake C.G., Jaffee E., and Pardoll D.M. Mechanisms of immune evasion by tumors. Adv Immunol 90 (2006) 51-81
3. Rabinovich G.A., Gabrilovich D., and Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25 (2007) 267-296
4. Dunn G.P., Old L.J., and Schreiber R.D. The three Es of cancer immunoediting. Annu Rev Immunol 22 (2004) 329-360
5. + regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22 (2004) 531-562
6. Terabe M., Matsui S., Noben-Trauth N., et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 1 (2000) 515-520
7. Colonna M., Trinchieri G., and Liu Y.J. Plasmacytoid dendritic cells in immunity. Nat Immunol 5 (2004) 1219-1226
8. Sotomayor E.M., Borrello I., Rattis F.M., et al. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood 98 (2001) 1070-1077
9. Morgan D.J., Kreuwel H.T., Fleck S., Levitsky H.I., Pardoll D.M., and Sherman L.A. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol 160 (1998) 643-651
10. + T cells. J Exp Med 198 (2003) 569-580
11. de Visser K.E., Eichten A., and Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6 (2006) 24-37
12. + T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 5 (1999) 780-787
13. Luo J.L., Maeda S., Hsu L.C., Yagita H., and Karin M. Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6 (2004) 297-305
14. Swann J.B., Vesely M.D., Silva A., et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci USA 105 (2008) 652-656
15. Balkwill F., Charles K.A., and Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7 (2005) 211-217
16. Thun M.J., Henley S.J., and Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94 (2002) 252-266
17. Rahme E., Barkun A.N., Toubouti Y., and Bardou M. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology 125 (2003) 404-412
18. Cottone M., Scimeca D., Mocciaro F., Civitavecchia G., Perricone G., and Orlando A. Clinical course of ulcerative colitis. Dig Liver Dis 40 Suppl. 2 (2008) S247-S252
19. Houghton A.M., Mouded M., and Shapiro S.D. Common origins of lung cancer and COPD. Nat Med 14 (2008) 1023-1024
20. Coley W.B. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci 105 (1893) 487-511
21. Mueller A., O'Rourke J., Chu P., et al. The role of antigenic drive and tumor-infiltrating accessory cells in the pathogenesis of helicobacter-induced mucosa-associated lymphoid tissue lymphoma. Am J Pathol 167 (2005) 797-812
22. Sutton P., O'Rourke J., Wilson J., Dixon M.F., and Lee A. Immunisation against Helicobacter felis infection protects against the development of gastric MALT Lymphoma. Vaccine 22 (2004) 2541-2546
23. Schaider H., Oka M., Bogenrieder T., et al. Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer 103 (2003) 335-343
24. Apetoh L., Ghiringhelli F., Tesniere A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13 (2007) 1050-1059
25. Nozawa H., Chiu C., and Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 103 (2006) 12493-12498
26. Bornstein P., and Sage E.H. Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 14 (2002) 608-616
27. Elola M.T., Wolfenstein-Todel C., Troncoso M.F., Vasta G.R., and Rabinovich G.A. Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci 64 (2007) 1679-1700
28. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315 (1986) 1650-1659
29. Podhajcer O.L., Benedetti L.G., Girotti M.R., Prada F., Salvatierra E., and Llera A.S. The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev 27 (2008) 691-705
30. Kaufmann B., Muller S., Hanisch F.G., et al. Structural variability of BM-40/SPARC/osteonectin glycosylation: implications for collagen affinity. Glycobiology 14 (2004) 609-619
31. Ledda M.F., Adris S., Bravo A.I., et al. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med 3 (1997) 171-175
32. Alvarez M.J., Prada F., Salvatierra E., et al. Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity. Cancer Res 65 (2005) 5123-5132
33. Prada F., Benedetti L.G., Bravo A.I., Alvarez M.J., Carbone C., and Podhajcer O.L. SPARC endogenous level, rather than fibroblast-produced SPARC or stroma reorganization induced by SPARC, is responsible for melanoma cell growth. J Invest Dermatol 127 (2007) 2618-2628
34. Sosa M.S., Girotti M.R., Salvatierra E., et al. Proteomic analysis identified N-cadherin, clusterin, and HSP27 as mediators of SPARC (secreted protein, acidic and rich in cysteines) activity in melanoma cells. Proteomics 7 (2007) 4123-4134
35. Barker T.H., Baneyx G., Cardo-Vila M., et al. SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity. J Biol Chem 280 (2005) 36483-36493
36. Shi Q., Bao S., Song L., et al. Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene 26 (2007) 4084-4094
37. Weaver M.S., Workman G.A., and Sage E.H. The copper-binding domain of sparc mediates cell survival in vitro via interaction with integrin beta 1 and activation of integrin-linked kinase. J Biol Chem 23 (2008) 23
38. Lane T.F., Iruela-Arispe M.L., and Sage E.H. Regulation of gene expression by SPARC during angiogenesis in vitro, changes in fibronectin, thrombospondin-1 and plasminogen activator inhibitor-1. J Biol Chem 267 (1992) 16736-16745
39. Lupetti R., Mortarini R., Panceri P., Sensi M., and Anichini A. Interaction with fibronectin regulates cytokine gene expression in human melanoma cells. Int J Cancer 66 (1996) 110-116
40. White E.S., Livant D.L., Markwart S., and Arenberg D.A. Monocyte-fibronectin interactions, via alpha(5)beta(1) integrin, induce expression of CXC chemokine-dependent angiogenic activity. J Immunol 167 (2001) 5362-5366
41. Prud'homme G.J. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 87 (2007) 1077-1091
42. Bassuk J.A., Pichler R., Rothmier J.D., et al. Induction of TGF-beta1 by the matricellular protein SPARC in a rat model of glomerulonephritis. Kidney Int 57 (2000) 117-128
43. Francki A., Bradshaw A.D., Bassuk J.A., Howe C.C., Couser W.G., and Sage E.H. SPARC regulates the expression of collagen type I and transforming growth factor-beta1 in mesangial cells. J Biol Chem 274 (1999) 32145-32152
44. Francki A., McClure T.D., Brekken R.A., et al. SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells. J Cell Biochem 91 (2004) 915-925
45. Schiemann B.J., Neil J.R., and Schiemann W.P. SPARC inhibits epithelial cell proliferation in part through stimulation of the TGF-beta-signaling system. Mol Biol Cell 14 (2003) 3977-3988
46. Zhou X., Tan F.K., Guo X., et al. Small interfering RNA inhibition of SPARC attenuates the profibrotic effect of transforming growth factor beta1 in cultured normal human fibroblasts. Arthritis Rheum 52 (2005) 257-261
47. Ford R., Wang G., Jannati P., et al. Modulation of SPARC expression during butyrate-induced terminal differentiation of cultured human keratinocytes: regulation via a TGF-beta-dependent pathway. Exp Cell Res 206 (1993) 261-275
48. Reed M.J., Vernon R.B., Abrass I.B., and Sage E.H. TGF-β 1 induces the expression of type I collagen and SPARC, and enhances contraction of collagen gels, by fibroblasts from young and aged donors. J Cell Physiol 158 (1994) 169-179
49. Shanker G., Olson D., Bone R., and Sawhney R. Regulation of extracellular matrix proteins by transforming growth factor beta1 in cultured pulmonary endothelial cells. Cell Biol Int 23 (1999) 61-72
50. Shiba H., Uchida Y., Kamihagi K., et al. Transforming growth factor-beta1 and basic fibroblast growth factor modulate osteocalcin and osteonectin/SPARC syntheses in vitamin-D-activated pulp cells. J Dent Res 80 (2001) 1653-1659
51. Wrana J.L., Overall C.M., and Sodek J. Regulation of the expression of a secreted acidic protein rich in cysteine (SPARC) in human fibroblasts by transforming growth factor beta. comparison of transcriptional and post-transcriptional control with fibronectin and type I collagen. Eur J Biochem 197 (1991) 519-528
52. Bierie B., and Moses H.L. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6 (2006) 506-520
53. Ahmadzadeh M., and Rosenberg S.A. TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J Immunol 174 (2005) 5215-5223
54. Kitamura M. Identification of an inhibitor targeting macrophage production of monocyte chemoattractant protein-1 as TGF-beta 1. J Immunol 159 (1997) 1404-1411
55. Chen J.J., Sun Y., and Nabel G.J. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 282 (1998) 1714-1717
56. Miwa K., Asano M., Horai R., Iwakura Y., Nagata S., and Suda T. Caspase 1-independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med 4 (1998) 1287-1292
57. Fridlender Z.G., Sun J., Kim S., et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 16 (2009) 183-194
58. Rodeck U., Bossler A., Graeven U., et al. Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res 54 (1994) 575-581
59. Mantovani A. The yin-yang of tumor-associated neutrophils. Cancer Cell 16 (2009) 173-174
60. Sangaletti S., Stoppacciaro A., Guiducci C., Torrisi M.R., and Colombo M.P. Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma. J Exp Med 198 (2003) 1475-1485
61. Sangaletti S., Di Carlo E., Gariboldi S., et al. Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. Cancer Res 68 (2008) 9050-9059
62. Yiu G.K., Chan W.Y., Ng S.W., et al. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 159 (2001) 609-622
63. Said N., Socha M.J., Olearczyk J.J., Elmarakby A.A., Imig J.D., and Motamed K. Normalization of the ovarian cancer microenvironment by SPARC. Mol Cancer Res 5 (2007) 1015-1030
64. Said N.A., Elmarakby A.A., Imig J.D., Fulton D.J., and Motamed K. SPARC ameliorates ovarian cancer-associated inflammation. Neoplasia 10 (2008) 1092-1104
65. Rempel S.A., Hawley R.C., Gutierrez J.A., et al. Splenic and immune alterations of the sparc-null mouse accompany a lack of immune response. Genes Immun 8 (2007) 262-274
66. Savani R.C., Zhou Z., Arguiri E., et al. Bleomycin-induced pulmonary injury in mice deficient in SPARC. Am J Physiol Lung Cell Mol Physiol 279 (2000) L743-750
67. Camino A.M., Atorrasagasti C., Maccio D., et al. Adenovirus-mediated inhibition of SPARC attenuates liver fibrosis in rats. J Gene Med 10 (2008) 993-1004
68. Bradshaw A.D., Puolakkainen P., Dasgupta J., Davidson J.M., Wight T.N., and Helene Sage E. SPARC-null mice display abnormalities in the dermis characterized by decreased collagen fibril diameter and reduced tensile strength. J Invest Dermatol 120 (2003) 949-955
69. Zhou X., Tan F.K., Guo X., and Arnett F.C. Attenuation of collagen production with small interfering RNA of SPARC in cultured fibroblasts from the skin of patients with scleroderma. Arthritis Rheum 54 (2006) 2626-2631
70. Rentz T.J., Poobalarahi F., Bornstein P., Sage E.H., and Bradshaw A.D. SPARC regulates processing of procollagen I and collagen fibrillogenesis in dermal fibroblasts. J Biol Chem 282 (2007) 22062-22071
71. Strandjord T.P., Madtes D.K., Weiss D.J., and Sage E.H. Collagen accumulation is decreased in SPARC-null mice with bleomycin-induced pulmonary fibrosis. Am J Physiol 277 (1999) L628-L635
72. Rotta G., Matteoli G., Mazzini E., Nuciforo P., Colombo M.P., and Rescigno M. Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of anti-Salmonella typhimurium immunity. J Exp Med 205 (2008) 657-667
73. Sangaletti S., Gioiosa L., Guiducci C., et al. Accelerated dendritic-cell migration and T-cell priming in SPARC-deficient mice. J Cell Sci 118 (2005) 3685-3694
74. Socha M.J., Manhiani M., Said N., Imig J.D., and Motamed K. Secreted protein acidic and rich in cysteine deficiency ameliorates renal inflammation and fibrosis in angiotensin hypertension. Am J Pathol 171 (2007) 1104-1112
75. Kyriakides T.R., and Bornstein P. Matricellular proteins as modulators of wound healing and the foreign body response. Thromb Haemost 90 (2003) 986-992
76. Lawler J., Sunday M., Thibert V., et al. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest 101 (1998) 982-992
77. Liaw L., Birk D.E., Ballas C.B., Whitsitt J.S., Davidson J.M., and Hogan B.L. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest 101 (1998) 1468-1478
78. Mansfield P.J., Boxer L.A., and Suchard S.J. Thrombospondin stimulates motility of human neutrophils. J Cell Biol 111 (1990) 3077-3086
79. Riser B.L., Mitra R., Perry D., Dixit V., and Varani J. Monocyte killing of human squamous epithelial cells: role for thrombospondin. Cancer Res 49 (1989) 6123-6129
80. Martin-Manso G., Galli S., Ridnour L.A., Tsokos M., Wink D.A., and Roberts D.D. Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells. Cancer Res 68 (2008) 7090-7099
81. Agah A., Kyriakides T.R., Lawler J., and Bornstein P. The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. Am J Pathol 161 (2002) 831-839
82. Murphy-Ullrich J.E., and Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 11 (2000) 59-69
83. Patarca R., Freeman G.J., Singh R.P., et al. Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. J Exp Med 170 (1989) 145-161
84. Rudland P.S., Platt-Higgins A., El-Tanani M., et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62 (2002) 3417-3427
85. Singhal H., Bautista D.S., Tonkin K.S., et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3 (1997) 605-611
86. Tuck A.B., O'Malley F.P., Singhal H., et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 79 (1998) 502-508
87. Rodrigues L.R., Teixeira J.A., Schmitt F.L., Paulsson M., and Lindmark-Mansson H. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev 16 (2007) 1087-1097
88. Saeki Y., Mima T., Ishii T., et al. Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications. Br J Haematol 123 (2003) 263-270
89. Hotte S.J., Winquist E.W., Stitt L., Wilson S.M., and Chambers A.F. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 95 (2002) 506-512
90. Angelucci A., Festuccia C., Gravina G.L., et al. Osteopontin enhances the cell proliferation induced by the epidermal growth factor in human prostate cancer cells. Prostate 59 (2004) 157-166
91. Bayless K.J., Meininger G.A., Scholtz J.M., and Davis G.E. Osteopontin is a ligand for the alpha4beta1 integrin. J Cell Sci 111 Pt 9 (1998) 1165-1174
92. Noti J.D. Adherence to osteopontin via alphavbeta3 suppresses phorbol ester-mediated apoptosis in MCF-7 breast cancer cells that overexpress protein kinase C-alpha. Int J Oncol 17 (2000) 1237-1243
93. Feng B., Rollo E.E., and Denhardt D.T. Osteopontin (OPN) may facilitate metastasis by protecting cells from macrophage NO-mediated cytotoxicity: evidence from cell lines down-regulated for OPN expression by a targeted ribozyme. Clin Exp Metastasis 13 (1995) 453-462
94. Rollo E.E., Laskin D.L., and Denhardt D.T. Osteopontin inhibits nitric oxide production and cytotoxicity by activated RAW264.7 macrophages. J Leukoc Biol 60 (1996) 397-404
95. Leali D., Dell'Era P., Stabile H., et al. Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. J Immunol 171 (2003) 1085-1093
96. Bourassa B., Monaghan S., and Rittling S.R. Impaired anti-tumor cytotoxicity of macrophages from osteopontin-deficient mice. Cell Immunol 227 (2004) 1-11
97. Takahashi K., Takahashi F., Hirama M., Tanabe K.K., and Fukuchi Y. Restoration of CD44S in non-small cell lung cancer cells enhanced their susceptibility to the macrophage cytotoxicity. Lung Cancer 41 (2003) 145-153
98. Hur E.M., Youssef S., Haws M.E., Zhang S.Y., Sobel R.A., and Steinman L. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol 8 (2007) 74-83
99. Okada H., Moriwaki K., Konishi K., et al. Tubular osteopontin expression in human glomerulonephritis and renal vasculitis. Am J Kidney Dis 36 (2000) 498-506
100. Ramaiah S.K., and Rittling S. Role of osteopontin in regulating hepatic inflammatory responses and toxic liver injury. Expert Opin Drug Metab Toxicol 3 (2007) 519-526
101. Mori R., Shaw T.J., and Martin P. Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarring. J Exp Med 205 (2008) 43-51
102. Behrem S., Zarkovic K., Eskinja N., and Jonjic N. Distribution pattern of tenascin-C in glioblastoma: correlation with angiogenesis and tumor cell proliferation. Pathol Oncol Res 11 (2005) 229-235
103. Ilmonen S., Jahkola T., Turunen J.P., Muhonen T., and Asko-Seljavaara S. Tenascin-C in primary malignant melanoma of the skin. Histopathology 45 (2004) 405-411
104. Kulla A., Liigant A., Piirsoo A., Rippin G., and Asser T. Tenascin expression patterns and cells of monocyte lineage: relationship in human gliomas. Mod Pathol 13 (2000) 56-67
105. Parekh K., Ramachandran S., Cooper J., Bigner D., Patterson A., and Mohanakumar T. Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes. Lung Cancer 47 (2005) 17-29
106. Talts J.F., Wirl G., Dictor M., Muller W.J., and Fassler R. Tenascin-C modulates tumor stroma and monocyte/macrophage recruitment but not tumor growth or metastasis in a mouse strain with spontaneous mammary cancer. J Cell Sci 112 Pt 12 (1999) 1855-1864
107. Lebensztejn D.M., Sobaniec-Lotowska M.E., Kaczmarski M., Voelker M., and Schuppan D. Matrix-derived serum markers in monitoring liver fibrosis in children with chronic hepatitis B treated with interferon alpha. World J Gastroenterol 12 (2006) 3338-3343
108. Nakahara H., Gabazza E.C., Fujimoto H., et al. Deficiency of tenascin C attenuates allergen-induced bronchial asthma in the mouse. Eur J Immunol 36 (2006) 3334-3345
109. Camby I., Le Mercier M., Lefranc F., and Kiss R. Galectin-1: a small protein with major functions. Glycobiology 16 (2006) 137R-157R
110. Ilarregui J.M., Bianco G.A., Toscano M.A., and Rabinovich G.A. The coming of age of galectins as immunomodulatory agents: impact of these carbohydrate binding proteins in T cell physiology and chronic inflammatory disorders. Ann Rheum Dis 64 (2005) iv96-iv103
111. Danguy A., Camby I., Kiss R., and Galectins cancer. Biochim Biophys Acta 1572 (2002) 285-293
112. Salatino M., Croci D.O., Bianco G.A., Ilarregui J.M., Toscano M.A., and Rabinovich G.A. Galectin-1 as a potential therapeutic target in autoimmune disorders and cancer. Expert Opin Biol Ther 8 (2008) 45-57
113. Rabinovich G.A., Ariel A., Hershkoviz R., Hirabayashi J., Kasai K.I., and Lider O. Specific inhibition of T-cell adhesion to extracellular matrix and proinflammatory cytokine secretion by human recombinant galectin-1. Immunology 97 (1999) 100-106
114. Santucci L., Fiorucci S., Rubinstein N., et al. Galectin-1 suppresses experimental colitis in mice. Gastroenterology 124 (2003) 1381-1394
115. Rabinovich G.A., Daly G., Dreja H., et al. Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J Exp Med 190 (1999) 385-398
116. Rubinstein N., Alvarez M., Zwirner N.W., et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell 5 (2004) 241-251
117. Peng W., Wang H.Y., Miyahara Y., Peng G., and Wang R.F. Tumor-associated galectin-3 modulates the function of tumor-reactive T cells. Cancer Res 68 (2008) 7228-7236
118. Zubieta M.R., Furman D., Barrio M., Bravo A.I., Domenichini E., and Mordoh J. Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies. Am J Pathol 168 (2006) 1666-1675
119. Dumont P., Berton A., Nagy N., et al. Expression of galectin-3 in the tumor immune response in colon cancer. Lab Invest 88 (2008) 896-906
120. Nagahara K., Arikawa T., Oomizu S., et al. Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J Immunol 181 (2008) 7660-7669
121. Pirinen R., Leinonen T., Bohm J., et al. Versican in nonsmall cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis. Hum Pathol 36 (2005) 44-50
122. Kim S., Takahashi H., Lin W.W., et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457 (2009) 102-106
123. Mantovani A. Cancer: inflaming metastasis. Nature 457 (2009) 36-37
124. Daniel C., Amann K., Hohenstein B., Bornstein P., and Hugo C. Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in experimental glomerulonephritis in mice. J Am Soc Nephrol 18 (2007) 788-798
125. Frey A.B., Wali A., Pass H., and Lonardo F. Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma. Histopathology 50 (2007) 720-726
126. Motamed K. SPARC (osteonectin/BM-40). Int J Biochem Cell Biol 31 (1999) 1363-1366
127. Funk S.E., and Sage E.H. Differential effects of SPARC and cationic SPARC peptides on DNA synthesis by endothelial cells and fibroblasts. J Cell Physiol 154 (1993) 53-63
128. Lane T.F., Iruela-Arispe M.L., Johnson R.S., and Sage E.H. SPARC is a source of copper-binding peptides that stimulate angiogenesis. J Cell Biol 125 (1994) 929-943
129. Chen Y., Wang X., Weng D., Tao S., Lv L., and Chen J. A TSP-1 functional fragment inhibits activation of latent transforming growth factor-beta1 derived from rat alveolar macrophage after bleomycin treatment. Exp Toxicol Pathol 61 (2009) 67-73
130. Senger D.R., Perruzzi C.A., Papadopoulos-Sergiou A., and Van de Water L. Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Mol Biol Cell 5 (1994) 565-574
131. Yasuda M., Nakano K., Yasumoto K., and Tanaka Y. CD44: functional relevance to inflammation and malignancy. Histol Histopathol 17 (2002) 945-950
132. Schor S.L., and Schor A.M. Phenotypic and genetic alterations in mammary stroma: implications for tumour progression. Breast Cancer Res 3 (2001) 373-379
133. Maquart F.X., Pasco S., Ramont L., Hornebeck W., and Monboisse J.C. An introduction to matrikines: extracellular matrix-derived peptides which regulate cell activity. Implication in tumor invasion. Crit Rev Oncol Hematol 49 (2004) 199-202
134. Brekken R.A., and Sage E.H. SPARC, a matricellular protein: at the crossroads of cell-matrix. Matrix Biol 19 (2000) 569-580
135. Sasaki T., Gohring W., Mann K., et al. Limited cleavage of extracellular matrix protein BM-40 by matrix metalloproteinases increases its affinity for collagens. J Biol Chem 272 (1997) 9237-9243
136. Adair-Kirk T.L., and Senior R.M. Fragments of extracellular matrix as mediators of inflammation. Int J Biochem Cell Biol 40 (2008) 1101-1110
137. Lin W.W., and Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117 (2007) 1175-1183